Novo Nordisk said on Thursday it plans to start late-stage trials of its experimental weight-loss drug amycretin in injection ...

Novo Nordisk is progressing both subcutaneous and oral versions of amycretin into Phase III trials for patients with obesity ...

Wegovy maker Novo Nordisk is moving its investigational amycretin asset into late-stage weight loss trials starting early ...

Novo Nordisk will begin phase 3 trials for amycretin in early 2026 following promising weight loss data and regulatory ...

NVO jumps nearly 6% in a week on amycretin pipeline boost and hedge fund interest, but competition looms large.

Novo Nordisk A/S (NYSE:NVO) is among the best bear market stocks to buy according to analysts. Novo Nordisk A/S (NYSE:NVO) ...

Novo Nordisk late Thursday announced that it will advance subcutaneous (SC) and oral amycretin into Phase III development in ...

Novo Nordisk plans to initiate late-stage trials for its next-gen weight-loss drug, amycretin, by early 2026. The drug mimics ...

Bagsværd, Denmark, 12 June 2025 – Novo Nordisk today announced that it will advance subcutaneous and oral amycretin into phase 3 development in weight management based on completed clinical ...

Novo Nordisk has announced plans to initiate late-stage trials for its amycretin injection and oral drugs targeting adults ...

Amycretin is a unimolecular long-acting GLP-1 and amylin receptor agonist under development by Novo Nordisk, to provide an ...